MAPK3 and hepatocellular carcinoma: To find the main mechanism of anti-tumor activity, we evaluated whether the PI3K/Akt or ERK1/2-MAPK pathways were activated by AS1411- or modified AS1411-aptamers, as these are key survival signaling pathways in HCC cells [14].